1
|
Veys C, Boulouard F, Benmoussa A, Jammes M, Brotin E, Rédini F, Poulain L, Gruchy N, Denoyelle C, Legendre F, Galera P. MiR-4270 acts as a tumor suppressor by directly targeting Bcl-xL in human osteosarcoma cells. Front Oncol 2023; 13:1220459. [PMID: 37719019 PMCID: PMC10501397 DOI: 10.3389/fonc.2023.1220459] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2023] [Accepted: 08/03/2023] [Indexed: 09/19/2023] Open
Abstract
Chondrosarcomas and osteosarcomas are malignant bone tumors with a poor prognosis when unresectable or metastasized. Moreover, radiotherapy and chemotherapy could be ineffective. MiRNAs represent an alternative therapeutic approach. Based on high-throughput functional screening, we identified four miRNAs with a potential antiproliferative effect on SW1353 chondrosarcoma cells. Individual functional validations were then performed in SW1353 cells, as well as in three osteosarcoma cell lines. The antiproliferative and cytotoxic effects of miRNAs were evaluated in comparison with a positive control, miR-342-5p. The cytotoxic effect of four selected miRNAs was not confirmed on SW1353 cells, but we unambiguously revealed that miR-4270 had a potent cytotoxic effect on HOS and MG-63 osteosarcoma cell lines, but not on SaOS-2 cell line. Furthermore, like miR-342-5p, miR-4270 induced apoptosis in these two cell lines. In addition, we provided the first report of Bcl-xL as a direct target of miR-4270. MiR-4270 also decreased the expression of the anti-apoptotic protein Mcl-1, and increased the expression of the pro-apoptotic protein Bak. Our findings demonstrated that miR-4270 has tumor suppressive activity in osteosarcoma cells, particularly through Bcl-xL downregulation.
Collapse
Affiliation(s)
- Clément Veys
- Normandie Univ., UNICAEN, BIOTARGEN, Caen, France
| | - Flavie Boulouard
- Normandie Univ., UNICAEN, BIOTARGEN, Caen, France
- Department of Genetics, Normandy Center for Genomic and Personalized Medicine, Caen University Hospital, Caen, France
| | - Abderrahim Benmoussa
- Normandie Univ., UNICAEN, BIOTARGEN, Caen, France
- Research Center of the UHC Sainte-Justine and Department of Nutrition, Université de Montréal, Montréal, QC, Canada
| | - Manon Jammes
- Normandie Univ., UNICAEN, BIOTARGEN, Caen, France
| | - Emilie Brotin
- Normandie Univ., UNICAEN, Federative Structure Normandie Oncology, US Platon, ImpedanCELL Platform, Caen, France
- Normandie Univ., UNICAEN, INSERM U1086 ANTICIPE, Biology and Innovative Therapeutics for Ovarian Cancer (BioTICLA), Caen, France
- UNICANCER, Comprehensive Cancer Center F. Baclesse, Caen, France
| | - Françoise Rédini
- UMR 1238 Phy-Os “Bone Sarcomas and Remodeling of Calcified Tissues”, INSERM, Nantes University, Nantes, France
| | - Laurent Poulain
- Normandie Univ., UNICAEN, INSERM U1086 ANTICIPE, Biology and Innovative Therapeutics for Ovarian Cancer (BioTICLA), Caen, France
- UNICANCER, Comprehensive Cancer Center F. Baclesse, Caen, France
| | - Nicolas Gruchy
- Normandie Univ., UNICAEN, BIOTARGEN, Caen, France
- Department of Genetics, Normandy Center for Genomic and Personalized Medicine, Caen University Hospital, Caen, France
| | - Christophe Denoyelle
- Normandie Univ., UNICAEN, Federative Structure Normandie Oncology, US Platon, ImpedanCELL Platform, Caen, France
- Normandie Univ., UNICAEN, INSERM U1086 ANTICIPE, Biology and Innovative Therapeutics for Ovarian Cancer (BioTICLA), Caen, France
- UNICANCER, Comprehensive Cancer Center F. Baclesse, Caen, France
| | | | | |
Collapse
|
2
|
Veys C, Benmoussa A, Contentin R, Duchemin A, Brotin E, Lafont JE, Saintigny Y, Poulain L, Denoyelle C, Demoor M, Legendre F, Galéra P. Tumor Suppressive Role of miR-342-5p in Human Chondrosarcoma Cells and 3D Organoids. Int J Mol Sci 2021; 22:ijms22115590. [PMID: 34070455 PMCID: PMC8197525 DOI: 10.3390/ijms22115590] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2021] [Revised: 05/19/2021] [Accepted: 05/19/2021] [Indexed: 01/07/2023] Open
Abstract
Chondrosarcomas are malignant bone tumors. Their abundant cartilage-like extracellular matrix and their hypoxic microenvironment contribute to their resistance to chemotherapy and radiotherapy, and no effective therapy is currently available. MicroRNAs (miRNAs) may be an interesting alternative in the development of therapeutic options. Here, for the first time in chondrosarcoma cells, we carried out high-throughput functional screening using impedancemetry, and identified five miRNAs with potential antiproliferative or chemosensitive effects on SW1353 chondrosarcoma cells. The cytotoxic effects of miR-342-5p and miR-491-5p were confirmed on three chondrosarcoma cell lines, using functional validation under normoxia and hypoxia. Both miRNAs induced apoptosis and miR-342-5p also induced autophagy. Western blots and luciferase reporter assays identified for the first time Bcl-2 as a direct target of miR-342-5p, and also Bcl-xL as a direct target of both miR-342-5p and miR-491-5p in chondrosarcoma cells. MiR-491-5p also inhibited EGFR expression. Finally, only miR-342-5p induced cell death on a relevant 3D chondrosarcoma organoid model under hypoxia that mimics the in vivo microenvironment. Altogether, our results revealed the tumor suppressive activity of miR-342-5p, and to a lesser extent of miR-491-5p, on chondrosarcoma lines. Through this study, we also confirmed the potential of Bcl-2 family members as therapeutic targets in chondrosarcomas.
Collapse
Affiliation(s)
- Clément Veys
- Normandie Univ, UNICAEN, BIOTARGEN, 14000 Caen, France; (C.V.); (A.B.); (R.C.); (A.D.); (M.D.); (F.L.)
| | - Abderrahim Benmoussa
- Normandie Univ, UNICAEN, BIOTARGEN, 14000 Caen, France; (C.V.); (A.B.); (R.C.); (A.D.); (M.D.); (F.L.)
- Research Center of the UHC Sainte-Justine and Department of Nutrition, Université de Montréal, Montréal, QC H3T 1C54, Canada
| | - Romain Contentin
- Normandie Univ, UNICAEN, BIOTARGEN, 14000 Caen, France; (C.V.); (A.B.); (R.C.); (A.D.); (M.D.); (F.L.)
| | - Amandine Duchemin
- Normandie Univ, UNICAEN, BIOTARGEN, 14000 Caen, France; (C.V.); (A.B.); (R.C.); (A.D.); (M.D.); (F.L.)
| | - Emilie Brotin
- Normandie Univ, UNICAEN, ImpedanCELL Platform, Federative Structure 4206 ICORE, 14000 Caen, France; (E.B.); (C.D.)
- Normandie Univ, UNICAEN, INSERM U1086 ANTICIPE, Biology and Innovative Therapeutics for Ovarian Cancer (BioTICLA), 14000 Caen, France;
- Unicancer, Comprehensive Cancer Center F. Baclesse, 14000 Caen, France
| | - Jérôme E. Lafont
- CNRS UMR 5305, Laboratory of Tissue Biology and Therapeutic Engineering, Université Claude Bernard Lyon 1, Univ Lyon, 69367 Lyon, France;
| | - Yannick Saintigny
- LARIA, iRCM, François Jacob Institute, DRF-CEA, 14000 Caen, France;
- Normandie Univ, ENSICAEN, UNICAEN, CEA, CNRS, UMR6252 CIMAP, 14000 Caen, France
| | - Laurent Poulain
- Normandie Univ, UNICAEN, INSERM U1086 ANTICIPE, Biology and Innovative Therapeutics for Ovarian Cancer (BioTICLA), 14000 Caen, France;
- Unicancer, Comprehensive Cancer Center F. Baclesse, 14000 Caen, France
| | - Christophe Denoyelle
- Normandie Univ, UNICAEN, ImpedanCELL Platform, Federative Structure 4206 ICORE, 14000 Caen, France; (E.B.); (C.D.)
- Normandie Univ, UNICAEN, INSERM U1086 ANTICIPE, Biology and Innovative Therapeutics for Ovarian Cancer (BioTICLA), 14000 Caen, France;
- Unicancer, Comprehensive Cancer Center F. Baclesse, 14000 Caen, France
| | - Magali Demoor
- Normandie Univ, UNICAEN, BIOTARGEN, 14000 Caen, France; (C.V.); (A.B.); (R.C.); (A.D.); (M.D.); (F.L.)
| | - Florence Legendre
- Normandie Univ, UNICAEN, BIOTARGEN, 14000 Caen, France; (C.V.); (A.B.); (R.C.); (A.D.); (M.D.); (F.L.)
| | - Philippe Galéra
- Normandie Univ, UNICAEN, BIOTARGEN, 14000 Caen, France; (C.V.); (A.B.); (R.C.); (A.D.); (M.D.); (F.L.)
- Correspondence:
| |
Collapse
|